Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, generates frequent news across human health, animal health and corporate finance. As a research-intensive biopharmaceutical company with more than a century of history developing medicines and vaccines, Merck regularly announces clinical trial milestones, regulatory decisions, business development transactions and capital markets activity.
Recent news highlights include oncology updates from Merck’s extensive KEYTRUDA program, such as positive Phase 3 data in muscle-invasive bladder cancer and new trials in non-small cell lung cancer using combinations like calderasib (MK-1084) with KEYTRUDA QLEX. The company also reports on progress in other therapeutic areas, including pulmonary arterial hypertension with WINREVAIR, Alzheimer’s disease candidates MK-2214 and MK-1167, and cardiovascular research with the oral PCSK9 inhibitor candidate enlicitide.
Investors following MRK news will also see announcements related to Merck Animal Health, such as the conditional U.S. FDA approval of EXZOLT CATTLE-CA1 for the prevention and treatment of New World screwworm larvae and the treatment and control of cattle fever tick, as well as updates on acquisitions like the planned merger with Cidara Therapeutics to add the influenza candidate CD388 to Merck’s respiratory portfolio.
Corporate and financial communications include quarterly earnings calls, participation in major healthcare conferences and disclosures about note offerings under the company’s shelf registration statement. This news page aggregates these developments so readers can review clinical, regulatory, strategic and financial updates related to Merck & Co., Inc. and its MRK stock in one place.
Merck (NYSE: MRK) has launched the VICTOR trial, a pivotal Phase 3 study of VERQUVO (vericiguat) aimed at treating adults with chronic heart failure and reduced ejection fraction. This randomized, placebo-controlled trial will enroll approximately 6,000 participants globally, focusing on patients with an ejection fraction of 40% or less who have not experienced a recent worsening heart failure event. The primary efficacy endpoint is the time to cardiovascular death or heart failure hospitalization. The trial is expected to conclude in 39 months and follows the successful VICTORIA study.
Organon reported Q3 2021 revenue of $1,600 million, down 1% from Q3 2020. Net income was $323 million or $1.27 per diluted share, a 42% decline year-over-year. Adjusted EBITDA fell 15% to $636 million, with a margin of 39.8%. The company affirmed its financial guidance and announced a quarterly dividend of $0.28 per share. Notably, Women’s Health revenue dropped 10%, while Biosimilars rose 41%. Organon is actively expanding through acquisitions and maintaining strong cash flow with $1,008 million in cash, despite high debt levels.
Organon (NYSE: OGN) has announced its acquisition of Forendo Pharma, a clinical-stage company focusing on innovative treatments for women’s health. The deal includes a $75 million upfront payment, with additional potential payments totaling up to $954 million based on milestones. Forendo's lead candidate, FOR-6219, is a novel oral HSD17B1 inhibitor for treating endometriosis and is entering Phase 2 clinical trials. This acquisition aligns with Organon’s commitment to addressing significant unmet needs in women's health, including conditions like endometriosis and polycystic ovarian syndrome (PCOS).
Merck (NYSE: MRK) and Ridgeback Biotherapeutics announced an agreement with the Japanese government to purchase approximately 1.6 million courses of molnupiravir, an oral antiviral for COVID-19, pending regulatory approval. The deal is valued at around $1.2 billion. Merck anticipates producing 10 million treatment courses by the end of 2021 and at least 20 million in 2022. The company has initiated various global supply agreements and aims to broaden access to molnupiravir through tiered pricing and licensing for generic versions.
Avoro Capital Advisors owns approximately 7% of Acceleron Pharma Inc. (XLRN) and opposes Merck's ($MRK) $180 per share tender offer. Avoro believes that now is not the right time to sell, citing expected significant value from upcoming STELLAR Phase 3 trial data within a year. They argue the offer undervalues Acceleron based on higher precedents and criticize the board for a flawed sale process with limited buyer outreach. Avoro is prepared to support Acceleron as an independent entity and will not tender its shares.
Merck (NYSE: MRK) and Ridgeback Biotherapeutics announced that the U.S. government will purchase an additional 1.4 million courses of molnupiravir, bringing the total commitment to approximately 3.1 million courses for around $2.2 billion. This procurement is contingent on Emergency Use Authorization (EUA) or FDA approval for molnupiravir, an oral antiviral treatment for COVID-19. Merck has been producing the drug at risk, expecting to deliver 10 million courses by year-end 2021, with capabilities to produce at least 20 million in 2022.
Merck has received antitrust clearance for its acquisition of Acceleron Pharma Inc. from competition authorities in Germany and Austria. The acquisition involves a cash tender offer of $180 per share, as announced on October 12, 2021. This step fulfills one of the necessary conditions for the tender offer's completion. The tender offer is set to expire on November 18, 2021, unless extended. The acquisition is anticipated to close in Q4 2021, pending other conditions detailed in the SEC filings.
Acceleron Pharma reported Q3 2021 revenue of $34.2 million, including $32.0 million in royalty revenue from REBLOZYL, up from $25.6 million last quarter. Merck agreed to acquire Acceleron for $180 per share, valuing the deal at approximately $11.5 billion, expected to close in Q4. The company has several ongoing Phase 3 trials for its therapies, including sotatercept for pulmonary hypertension and ACE-1334 for systemic sclerosis-associated lung disease. Cash reserves stand at $652.5 million.
The U.K. Medicines and Healthcare Products Regulatory Agency has authorized molnupiravir, an oral antiviral, for treating mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 test and risk factors for severe illness. This marks a significant step as it is the first oral antiviral to receive such authorization. Merck (NYSE: MRK) is working to gain additional approvals globally, with applications submitted to the FDA and the European Medicines Agency. The authorization is based on positive results from the Phase 3 MOVe-OUT trial, indicating a 50% reduction in hospitalization or death risk.
Merck announced significant findings for KEYTRUDA at the SMR 2021 Congress, showcasing its effectiveness in treating melanoma. The exploratory 7-year follow-up data from KEYNOTE-006 showed a median overall survival of 32.7 months for KEYTRUDA versus 15.9 months for ipilimumab. The 7-year survival rates were 37.8% vs. 25.3%, respectively. In the KEYNOTE-716 trial, KEYTRUDA demonstrated a 39% reduction in the risk of disease recurrence compared to placebo in patients with resected stage IIB/IIC melanoma. Safety profiles were consistent across studies, with no new safety signals identified.